Document is current
Any future updates will be listed below
-
Authors
Ardeshir, Amir https://orcid.org/0000-0002-4330-4659
O’Hagan, Daniel
Mehta, Isha https://orcid.org/0000-0002-6009-0787
Shandilya, Siddhartha https://orcid.org/0000-0002-9179-5878
Hopkins, Lincoln L. J. https://orcid.org/0000-0002-3874-3585
Adamson, Lourdes
Kuroda, Marcelo J.
Hahn, Patricia A. https://orcid.org/0000-0002-4338-4660
da Costa, Lucas A. B.
Fuchs, Sebastian P.
Martinez-Navio, Jose M. https://orcid.org/0000-0003-0560-5407
Gardner, Matthew R. https://orcid.org/0000-0003-2872-7597
Van Rompay, Koen K. A. https://orcid.org/0000-0002-7375-1337
Magnani, Diogo M. https://orcid.org/0000-0002-1773-2406
Lifson, Jeffrey D.
Gao, Guangping https://orcid.org/0000-0003-0097-9012
Farzan, Michael https://orcid.org/0000-0002-2990-5319
Desrosiers, Ronald C.
Das, Jishnu https://orcid.org/0000-0002-5747-064X
Martins, Mauricio A. https://orcid.org/0000-0001-8336-216X
- License Information
-
More Information
Article History
Received: 2 May 2024
Accepted: 27 June 2025
First Online: 30 July 2025
Change Date: 19 November 2025
Change Type: Update
Change Details: In the version of this article initially published, the Acknowledgements did not include thanks for funding from the HIV/AIDS and Emerging Infectious Diseases Institute at the University of Miami through the State of Florida Funding Initiative, as is now amended in the HTML and PDF versions of the article.
Competing interests
: M.A.M., M.R.G. and M.F. have significant financial interests in Emmune Inc., a company that is developing HIV immunotherapies based on the immunoadhesin eCD4-Ig. These potential conflicts of interest are being managed by the authors’ respective institutions. The other authors declare no competing interests.
